Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
Amgen, Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. The Company manufactures and markets human therapeutic products, including Epogen, Neupogen, Aranesp, Neulasta and Kineret. Amgen focuses its research and development efforts on therapeutics delivered in the form of proteins, monoclonal antibodies and small molecules in the areas of nephrology, cancer, inflammation and neurology and metabolism. The Company has research facilities in the United States, and has clinical development staff in the United States, the European Union, Canada, Australia and Japan. In July 2002, Amgen acquired Immunex Corporation, a biopharmaceutical company dedicated to developing immune system science to protect human health. Immunex had successfully developed two products, Enbrel and Leukine, and was marketing four products treating multiple indications, Enbrel, Leukine, Novantrone and Thioplex.

Financial Information
Amgen, Inc. is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. For the six months ended 6/02, revenues rose 20% to $2.26 billion. Net income rose 20% to $753.3 million. Revenues benefited from increased sales of anemia treatments EPOGEN(R) and Aransep(TM), and the launch of Neulasta(TM). Net income also reflects lower R&D costs as a percentage of sales.